PDEX Quote, Financials, Valuation and Earnings

Outset Medical has a net margin of 12.15% compared to Pro-Dex's net margin of -87.01%. Pro-Dex's return on equity of 21.59% beat Outset Medical's return on equity of -178.08%.

Pro-Dex has a consensus price target of $54.00, signalling downside risk potential of -16.78%. On the other hand Outset Medical has an analysts' consensus of $21.75 which suggests that it could grow by 87.82%. Given that Outset Medical has higher upside potential than Pro-Dex, analysts believe Outset Medical is more attractive than Pro-Dex.

Pro-Dex has a beta of 0.400, which suggesting that the stock is 60.026% less volatile than S&P 500. In comparison Outset Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outset Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Outset Medical pays out -- of its earnings as a dividend.

Pro-Dex quarterly revenues are $16.8M, which are smaller than Outset Medical quarterly revenues of $29.5M. Pro-Dex's net income of $2M is higher than Outset Medical's net income of -$25.6M. Notably, Pro-Dex's price-to-earnings ratio is 32.45x while Outset Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 3.62x versus 0.35x for Outset Medical. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 12.15% compared to Pro-Dex's net margin of 16.85%. Pro-Dex's return on equity of 21.59% beat Insulet's return on equity of 43.11%.

Pro-Dex has a consensus price target of $54.00, signalling downside risk potential of -16.78%. On the other hand Insulet has an analysts' consensus of $312.27 which suggests that it could grow by 19.78%. Given that Insulet has higher upside potential than Pro-Dex, analysts believe Insulet is more attractive than Pro-Dex.

Pro-Dex has a beta of 0.400, which suggesting that the stock is 60.026% less volatile than S&P 500. In comparison Insulet has a beta of 1.300, suggesting its more volatile than the S&P 500 by 30.008%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pro-Dex pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Pro-Dex quarterly revenues are $16.8M, which are smaller than Insulet quarterly revenues of $597.5M. Pro-Dex's net income of $2M is lower than Insulet's net income of $100.7M. Notably, Pro-Dex's price-to-earnings ratio is 32.45x while Insulet's PE ratio is 45.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 3.62x versus 9.30x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 12.15% compared to Pro-Dex's net margin of 8.48%. Pro-Dex's return on equity of 21.59% beat Stryker's return on equity of 15.22%.

Pro-Dex has a consensus price target of $54.00, signalling downside risk potential of -16.78%. On the other hand Stryker has an analysts' consensus of $421.86 which suggests that it could grow by 15.56%. Given that Stryker has higher upside potential than Pro-Dex, analysts believe Stryker is more attractive than Pro-Dex.

Pro-Dex has a beta of 0.400, which suggesting that the stock is 60.026% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.107%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.9% to investors and pays a quarterly dividend of $0.84 per share. Pro-Dex pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pro-Dex quarterly revenues are $16.8M, which are smaller than Stryker quarterly revenues of $6.4B. Pro-Dex's net income of $2M is lower than Stryker's net income of $546M. Notably, Pro-Dex's price-to-earnings ratio is 32.45x while Stryker's PE ratio is 47.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 3.62x versus 6.23x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services has a net margin of 12.15% compared to Pro-Dex's net margin of 12.87%. Pro-Dex's return on equity of 21.59% beat West Pharmaceutical Services's return on equity of 17.47%.

Pro-Dex has a consensus price target of $54.00, signalling downside risk potential of -16.78%. On the other hand West Pharmaceutical Services has an analysts' consensus of $281.83 which suggests that it could grow by 31.36%. Given that West Pharmaceutical Services has higher upside potential than Pro-Dex, analysts believe West Pharmaceutical Services is more attractive than Pro-Dex.

Pro-Dex has a beta of 0.400, which suggesting that the stock is 60.026% less volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.221, suggesting its more volatile than the S&P 500 by 22.112%.

Pro-Dex has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services offers a yield of 0.38% to investors and pays a quarterly dividend of $0.21 per share. Pro-Dex pays -- of its earnings as a dividend. West Pharmaceutical Services pays out 12% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pro-Dex quarterly revenues are $16.8M, which are smaller than West Pharmaceutical Services quarterly revenues of $698M. Pro-Dex's net income of $2M is lower than West Pharmaceutical Services's net income of $89.8M. Notably, Pro-Dex's price-to-earnings ratio is 32.45x while West Pharmaceutical Services's PE ratio is 33.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pro-Dex is 3.62x versus 5.44x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.